Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Tumor necrosis factor receptor 1 (TNFR1) is a single-spanning type I transmembrane protein with several cysteine-rich extracellular domains, and also known as one of the major receptors of TNFα. Due ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

A recently study published in Nutrients reports that the regular consumption of mangoes may improve inflammation, insulin ...

Another significant advancement is the evaluation of 2-deoxy-2-[18F]fluoro glucaric acid (FGA) as a PET tracer for tumor necrosis. In a study involving mice with lung cancer, the uptake of [18 F ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

Breast cancer, one of the most common cancers among women, could soon benefit from a new therapeutic approach. A new molecule ...

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...